In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rami Katkhuda has given his Buy rating due to a combination of factors, including Amylyx’s solid financial footing and the advancing late-stage development of avexitide for post-bariatric hypoglycemia (PBH). The company ended Q1 2026 with approximately $279.8M in cash and equivalents, which management believes is sufficient to fund operations into 2028, reducing near- to mid-term financing risk.
Katkhuda also points to the pivotal Phase III LUCIDITY trial of avexitide as a key value driver, noting that the study design is underpinned by strong mechanistic rationale and a robust body of prior PBH data that meaningfully de-risks the program. With a potential 2027 launch, ongoing regulatory preparations, expansion of commercial infrastructure, a new ICD-10 code to support disease recognition, and a promising early-stage GLP-1 antagonist candidate (AMX0138) progressing toward the clinic, he sees attractive upside relative to the unchanged $24 price target.
Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Disc Medicine. According to TipRanks, Katkhuda has an average return of 31.9% and a 54.36% success rate on recommended stocks.
In another report released on May 5, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.